IL-13 Targeting Biologics for the Treatment of Atopic Dermatitis : Episode 17

Opinion

Video

March 4, 2025

Emerging Treatment Options in Atopic Dermatitis

Panelists discuss new treatment options in atopic dermatitis (AD) that they are excited about, highlighting promising therapies and advancements, and share clinical pearls for colleagues, emphasizing best practices and insights to optimize patient care and outcomes.

EP: 1.Heterogenous Presentation Of Atopic Dermatitis

EP: 2.Use of Biopsy and Diagnosing New-Onset AD

EP: 3.Treatment Options in Atopic Dermatitis

EP: 4.Improvement in Standard of Care in Atopic Dermatitis

EP: 5.Improvement in Patients’ Qualify of Life with Atopic Dermatitis Treatments

EP: 6.Guidance for Moving to Advanced Systemic Therapy and Biologic Agents

EP: 7.IL-13–Targeting Agents in Atopic dermatitis

EP: 8.Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

EP: 9.Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

EP: 10.Switching or Staying Within the Treatment Class

EP: 11.Use of Combination Therapy in Atopic Dermatitis

EP: 12.Safety Data With Biologics in Atopic Dermatitis

EP: 13.Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

EP: 14.Lebrikizumab in Patients With Skin of Color (ADmirable)

EP: 15.Treatment Nonresponders in Atopic Dermatitis

EP: 16.Considerations for Switching Treatment

EP: 17.Emerging Treatment Options in Atopic Dermatitis

Video content above is prompted by the following:

What new options in AD are you excited about?
What clinical pearls would you like to share with colleagues?

Related Videos

Improving Care for ISM With Better Diagnosis, Disease Characterization, with Thanai Pongdee, MD

Skin of Color Savvy: Hair Loss Misconceptions, Clinical Insights, and Management, with Janiene Luke, MD, and Victoria Barbosa, MD, MPH

John Barbieri, MD, MBA | Credit: Brigham and Women's Hospital

5 experts in this video

3 experts are featured in this series.

5 experts in this video

Achieving Chronic Spontaneous and Inducible Urticaria Control With Barzolvolimab, with Martin Metz, MD

Scott Commins, MD, PhD I Credit: UNC School of Medicine

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.